In vitro and in vivo analyses on anti-NSCLC activity of apatinib: rediscovery of a new drug target V600E mutation.

Chen, Jiani; Zhai, Jingwen; Li, Mingming; Liu, Shiyi; Gong, Xiaobin; Yu, Hongyu; Wei, Hua; Chen, Wansheng

Chen, Jiani; Zhai, Jingwen; Li, Mingming; Liu, Shiyi; Gong, Xiaobin; Yu, Hongyu; Wei, Hua; Chen, Wansheng.

Afiliação

Chen J; Medical Guarantee Center, Second Affiliated Hospital of Naval Medical University, Shanghai, 200003, China.
Zhai J; Medical Guarantee Center, Second Affiliated Hospital of Naval Medical University, Shanghai, 200003, China.
Li M; Medical Guarantee Center, Second Affiliated Hospital of Naval Medical University, Shanghai, 200003, China.
Liu S; Medical Guarantee Center, Second Affiliated Hospital of Naval Medical University, Shanghai, 200003, China.
Gong X; Medical Guarantee Center, Second Affiliated Hospital of Naval Medical University, Shanghai, 200003, China.
Yu H; Department of Pathology, Second Affiliated Hospital of Naval Medical University, Shanghai, 200003, China. yuhongyu795@hotmail.com.
Wei H; Medical Guarantee Center, Second Affiliated Hospital of Naval Medical University, Shanghai, 200003, China. weihua@smmu.edu.cn.
Chen W; Medical Guarantee Center, Second Affiliated Hospital of Naval Medical University, Shanghai, 200003, China. chenwanshengchzh@126.com.

Cancer Cell Int ; 23(1): 21, 2023 Feb 09.

Article em En | MEDLINE | ID: mdl-36759818

Palavras-chave

Apatinib; BRAF V600E; CYP2D6; CYP3A4; HPLC-MS/MS; Non-small-cell lung cancer (NSCLC); P-gp

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancer Cell Int Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google